Nxera Pharma (4565) Stock Overview
Develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
4565 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥986.00 |
| 52 Week High | JP¥1,357.00 |
| 52 Week Low | JP¥668.00 |
| Beta | 0.31 |
| 1 Month Change | 5.01% |
| 3 Month Change | 7.29% |
| 1 Year Change | -24.04% |
| 3 Year Change | -49.15% |
| 5 Year Change | -28.50% |
| Change since IPO | -51.55% |
Recent News & Updates
Recent updates
Personalized Oral Therapies Will Transform Global Healthcare Markets
Key Takeaways Diverse pipeline and strategic partnerships position Nxera Pharma to capitalize on demand for innovative, accessible therapies in obesity, neuropsychiatric, and immunology markets. Advances in digital drug discovery and commercialization efforts are expected to enhance R&D efficiency, reduce risk, and expand future earnings and market share.Getting In Cheap On Nxera Pharma Co., Ltd. (TSE:4565) Might Be Difficult
Apr 04
Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Sep 25Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable
Jun 26Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Mar 08Shareholder Returns
| 4565 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.4% | -0.4% | 1.8% |
| 1Y | -24.0% | -4.5% | 22.1% |
Return vs Industry: 4565 underperformed the JP Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: 4565 underperformed the JP Market which returned 22.1% over the past year.
Price Volatility
| 4565 volatility | |
|---|---|
| 4565 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 3.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.7% |
Stable Share Price: 4565's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4565's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 389 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology.
Nxera Pharma Co., Ltd. Fundamentals Summary
| 4565 fundamental statistics | |
|---|---|
| Market cap | JP¥89.23b |
| Earnings (TTM) | -JP¥3.27b |
| Revenue (TTM) | JP¥31.21b |
Is 4565 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4565 income statement (TTM) | |
|---|---|
| Revenue | JP¥31.21b |
| Cost of Revenue | JP¥7.60b |
| Gross Profit | JP¥23.61b |
| Other Expenses | JP¥26.88b |
| Earnings | -JP¥3.27b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 31, 2025
| Earnings per share (EPS) | -36.16 |
| Gross Margin | 75.66% |
| Net Profit Margin | -10.48% |
| Debt/Equity Ratio | 92.3% |
How did 4565 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/13 19:06 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nxera Pharma Co., Ltd. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| null null | Credit Suisse |